The REPROCELL Blog

Do animal experiments translate to humans? A report by Elsevier and Bayer uses big data to shed new light on a hotly debated topic

[fa icon="calendar'] May 25, 2018 11:03:43 AM / by Dr David Bunton

[fa icon="comment"] 0 Comments

The use of animals to predict the risk of adverse effects in humans is a long-standing debate within Pharma and also in society at large. Moreover, safety issues leading to clinical attrition remain a problem and a major financial drain on Pharma.

Continue reading [fa icon="long-arrow-right"]

Factors to consider when planning a iPSC reprogramming project

[fa icon="calendar'] May 18, 2018 8:03:40 AM / by Dr Sarah Eminli-Meissner

[fa icon="comment"] 0 Comments

When you are considering beginning a project involving iPSC reprogramming, there are several factors to consider when choosing a reprogramming technology and a service provider.

Continue reading [fa icon="long-arrow-right"]

REPROCELL’s Dr David Bunton on April 2018 Trade Mission to China with Scottish First Minister Nicola Sturgeon

[fa icon="calendar'] Apr 18, 2018 4:44:17 AM / by Simon Padbury

[fa icon="comment"] 0 Comments

REPROCELL Europe’s CEO, Dr David Bunton, was part of last week's  trade mission to China undertaken by the Scottish First Minister, the Rt. Hon. Nicola Sturgeon MSP.

Continue reading [fa icon="long-arrow-right"]

Characterization of iPSCs by Immunocytochemistry

[fa icon="calendar'] Apr 5, 2018 12:20:38 PM / by Zara Puckrin posted in Drug Discovery, Stem Cells

[fa icon="comment"] 0 Comments

As part of our contract services at REPROCELL, we offer induced pluripotent stem cell (iPSC) characterization by immunocytochemistry (ICC). Planning ICC can be tricky, as it requires careful selection of compatible antibodies and fluorochromes. However, if successful, the results are fantastic! Don’t waste valuable research time performing ICC, and let our experts do the work for you!

Continue reading [fa icon="long-arrow-right"]

The Benefits of Human Tissue to Drug Discovery and Development

[fa icon="calendar'] Mar 27, 2018 7:00:00 AM / by Karen Mcaulay posted in Drug Discovery, Human Tissues

[fa icon="comment"] 0 Comments

Progressive and innovative Pharmaceutical and Biotechnology companies ask themselves several key questions when it comes to Drug Discovery and Development:

• How and where can we be research smarter? 
• How can we reduce uncertainty? 
• How can we better predict efficacy and safety? 
• How can we reduce costs?

One route to making the drug discovery process smarter and more efficient is to use human tissue at one or more stages in the development process.

Continue reading [fa icon="long-arrow-right"]

REPROCELL’s David Bunton addresses the Scottish Parliament

[fa icon="calendar'] Mar 21, 2018 11:58:30 AM / by Abbie Wishart posted in Drug Discovery, Scotland's Economic Performance, Research & Development, Government Partnership, SME

[fa icon="comment"] 0 Comments

On Tuesday 20th March 2018 REPROCELL Europe Ltd’s CEO Dr David Bunton appeared in front of the Economy, Jobs and Fair Work Committee at the Scottish Parliament to discuss Scotland’s Economic performance.  He was also joined by:

• Dr Diane Harbison, CEO, of Stratified Medicine Scotland

• Claire Mack, CEO, of Scottish Renewables

• Gareth Wynn, Stakeholder and Communications Director, Oil & Gas UK

Continue reading [fa icon="long-arrow-right"]

Patient-derived tumor organoids recapitulated clinical treatments

[fa icon="calendar'] Mar 14, 2018 9:07:57 AM / by Inês A. Silva posted in Drug Discovery

[fa icon="comment"] 0 Comments

The pharmaceutical industry suffers from very high rates of clinical failure, because preclinical predictions of efficacy often fail to realize a clinical benefit. In part, this can be attributed to an over-reliance on animal models of efficacy, which often do not fully predict human responses to drugs. Two areas where very few predictive models are available is inflammatory bowel disease (IBD)—which includes ulcerative colitis and Crohn’s disease—and gastrointestinal cancer—specifically cancer of the small intestine and the colon. REPROCELL has set out to solve these challenges by developing new preclinical tests based on human tissues.

Continue reading [fa icon="long-arrow-right"]

Five reasons to choose StemRNA 3rd Gen reprogramming

[fa icon="calendar'] Mar 2, 2018 10:07:01 AM / by Anca Haralambie posted in iPSC Reprogramming, Drug Discovery, Stem Cells

[fa icon="comment"] 0 Comments

RNA Reprogramming is used globally for the generation of integration-free induced pluripotent stem cells (iPSCs) by researchers in biotech, academia, research hospitals and government agencies. This reprogramming method is gaining more and more interest and core labs and biotech companies focusing on regenerative medicine and GMP compatibility are adopting this technology and make it their standard.

Continue reading [fa icon="long-arrow-right"]

Inserts or Plates: Which format for your 3D cell culture

[fa icon="calendar'] Feb 14, 2018 10:27:49 AM / by Frederique Tholozan posted in Drug Discovery, 3D Cell Culture, Bio-engineered Tissue Models

[fa icon="comment"] 0 Comments

 

3D cell culture. You've heard about it, you've read about it. You're probably daunted by the plethora of techniques available out there, but you want to join the growing number of scientists publishing in the 3D field or you hope it will make your drug discovery pipeline more effective.

But how should you do it? What's the best for your cells?

Continue reading [fa icon="long-arrow-right"]

Cost Effective, Lab-scale iPS Cell Spheroid Culture

[fa icon="calendar'] Feb 9, 2018 10:40:47 AM / by Robert Annand posted in 3D Cell Culture, Stem Cells

[fa icon="comment"] 0 Comments

Many stem cell projects expand to a point where standard culture methods—plates, dishes, flasks, etc.—no longer yield sufficient cells to meet the growing needs for differentiation and regenerative medicine. At this point, larger scale options are required. Traditional bioreactors provide large volume cell culture of liters to hundreds of liters, but they are expensive to buy and expensive to operate. New small scale bioreactors fill the niche between these two extremes perfectly, providing increased cell production over plates or dishes, while being cost-effective to buy and operate.

Continue reading [fa icon="long-arrow-right"]

Stay informed

Sign up to receive information from REPROCELL about our products, services, applications, promotions, and news (includes a weekly blog update email).

Recent Posts